Status:
UNKNOWN
Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
SARS-CoV 2
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Covid-19 infection is due to SARS-CoV-2 member of the Coronavirus family represented by SARS- and MERS-CoVwith neuronal tropism capacity for the brainstem and thalami. Dexmedetomidine has(i) central a...
Detailed Description
Coronaviruses (CoV) cause enteric and respiratory diseases. Most human CoVs, such as hCoV - 229E, OC43, NL63 and HKU1, cause mild respiratory disease, but the global spread of two previously well-know...
Eligibility Criteria
Inclusion
- Patient ≥ 18 years at time of inclusion
- Hospitalized in intensive care unit (ICU)
- Administration of dexmedetomidine scheduled for 7 days
- Intubated/ventilated patient infected with SARS-CoV-2 (Covid-19 positive patient)
- Patient affiliated to a social security system (French State medical aid excluded)
- Hemoglobin level ≥ 9 g /dL
- Patient or parent / close / trusted person having been informed about the study and having given informed consent (or inclusion procedure in an emergency situation)
Exclusion
- Protected major (under safeguardship, curatorship or guardianship)
- Pregnancy or breastfeeding
- Contra-indication to dexmedetomidine administration
Key Trial Info
Start Date :
April 24 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 24 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04413864
Start Date
April 24 2020
End Date
October 24 2022
Last Update
June 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Intensive Care Unit and Respiratory division ; Groupe hospitalier Pitie-Salpetriere and Universite Pierre et Marie Curie Paris 6
Paris, France, 75013